Adjuvant Therapies for Cancer Treatment: 2nd Edition

Dear Colleagues,

To improve cancer survival and prevent the recurrence of the disease and metastasis, we need to find new compounds and therapeutic strategies, as well as apply drug repurposing and combined therapies. This means that better adjuvant therapies to improve cancer cures need to be found in the next decade.

Adjuvant therapy may take the form of chemotherapy, radiotherapy, biological therapy, hormone therapy, and targeted therapy.

Adjuvant therapy is used after an initial treatment (such as surgery) or before as a neoadjuvant. Both applications have advantages (such as reducing tumor size, preventing tumor cells from spreading/metastasis, and eliminating any remaining malignant cells after surgery and disease recurrence) and disadvantages (such as serious side effects).

Omics studies and biological approaches have brought about a lot of knowledge of alterations and signaling deregulations in several cancer types and profiles related to outcome and drug efficacy. Cancer resistance occurs in different types of tumors and patients under different treatments, where some therapies are associated with specific resistance mechanisms (such as drug efflux, autophagy, apoptosis blockage, metabolism reprogramming, mutations, and stemness). However, the next steps in oncology will be to connect molecular data with clinical practice and offer a potential and specific protocol to the patient for cancer treatment.

This Special Issue is dedicated to illustrating new findings in adjuvant therapy applied for cancer treatment and highlighting the gaps and new directions in this field.

Prof. Dr. Fuyi Wang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.